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Abstract
AIM: To explore the potential association between single-nucleotide polymorphisms (SNPs) and haplotypes of the
CHRNA5-CHRNA3-CHRNB4 gene cluster and the non–small cell lung cancer (NSCLC) susceptibility in never-smoking
Chinese. METHODS: A case-control study was conducted with 200 NSCLC patients and 200 healthy controls,
matched on age and sex. Five SNPs distributed in CHRNA5-CHRNA3-CHRNB4 gene cluster were selected for geno-
typing. The association between genotype and lung cancer risk was evaluated by computing the odds ratio (OR) and
95% confidence interval (CI) from multivariate unconditional logistic regression analyses with adjustment for gender
and age. RESULTS: For CHRNA3 rs578776 status, data were available in 199 NSCLC patients and 199 controls. The
G/G homozygote in CHRNB4 rs7178270 had a reduced risk of developing NSCLC (OR= 0.553; 95%CI = 0.309–0.989;
P = .0437), especially squamous cell carcinoma (SQC) (OR = 0.344; 95% CI = 0.161–0.732; P = .0043), compared
with those who carry at least one C allele (C/C and C/G). The polymorphisms of rs578776, rs938682, rs17486278,
and rs11637635 were not significantly different between controls and cases or between controls and histologic sub-
groups, adenocarcinoma and SQC, respectively. CONCLUSIONS: In our study, we found that the SNP of CHRNB4
rs7178270 is significantly associatedwith reduced risk of NSCLC, especially with reduced risk of SQC in never-smoking
Chinese population.
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Introduction
The lung and bronchus cancer was the most common fatal cancer in
men and women in the United States [1]. Although smoking is the pri-
mary risk factor for developing lung cancer [2,3], the fact remains that
only a portion of smokers (usually <20%) develop lung cancer during
their lifetime. Chromosome 15q25 was the susceptibility zone for lung
cancer development [4–6]. Recently, the single-nucleotide polymor-
phisms (SNPs) in CHRNA5 (rs17486278 and rs11637635)–CHRNA3
(rs578776 and rs938682)–CHRNB4 (rs7178270) gene cluster, which
is located on chromosome 15q25, were found to be associated with lung
cancer in the genome-wide scan in African-Americans and European
populations [7,8]. In these studies, the lung cancer cases included a
large percentage of smokers. These results make it difficult to deter-
mine whether these loci are associated with lung carcinogenesis or
tobacco use, or perhaps both. Moreover, a substantial proportion of
lung cancer in East Asian women occurs among nonsmokers, who
interestingly have a relatively high rate of lung cancer [9]. Accumulat-
ing studies have suggested that lung cancer occurring in never smokers
has different molecular profiles [10] and different response to targeted
therapy [11,12].
On the basis of these findings, the question was raised whether
the variants of CHRNA5 (rs17486278 and rs11637635)–CHRNA3
(rs578776 and rs938682)–CHRNB4 (rs7178270) gene cluster may
also be associated with the susceptibility of non–small cell lung cancer
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(NSCLC) in Chinese population after eliminated interference of
tobacco. No report was published previously about this question.
So, we conducted this case-control study to examine CHRNA5-
CHRNA3-CHRNB4 gene cluster polymorphisms with risks for
NSCLC and further stratified on the basis of two major histologic
subtypes of NSCLC [adenocarcinoma (ADC) and squamous cell
carcinoma (SQC)] in never-smoking Chinese population.
Materials and Methods
Case-control Study
All cases and controls were people who never smoked and lived in
Southeast China. The eligible cases and controls were treated and
examined at the Zhejiang Cancer Hospital and the Second Affiliated
Hospital of Zhejiang Chinese University. The participants consisted
of 200 patients (145 ADC and 55 SQC patients) and 200 healthy
controls. Participants have no history of previous primary cancer
other than lung cancer. The controls were free from lung-related
diseases to avoid probable interferences from overlapping genes.
All subjects provided their informed consent approved by the Ethic
Committee of Zhejiang Cancer Hospital.
SNP Selection
The SNPs detected in this study included the five SNPs (rs17486278
and rs11637635 in CHRNA5; rs578776 and rs938682 in CHRNA3;
rs7178270 in CHRNB4) that have not been previously reported in a
Chinese population.
DNA Preparation and Genotyping
DNA was isolated from whole blood using the AxyPrep Blood
Genomic DNA Miniprep Kit (Axygen Biosciences, Union City,
CA). Primers for polymerase chain reaction and single-base exten-
sion were designed by using the Assay Designers software version
3.0 (Sequenom) and were processed following standard protocols
for iPLEX chemistry. Primers were synthesized by Sangon Biotech
(Shanghai, China; Table 1). Genotype calling was performed in real
time with MassARRAY RT software version 3.0 and analyzed by using
the MassARRAY Typer software version 3.4.
Statistical Analysis
Hardy-Weinberg equilibrium (HWE) testing was carried out for
all five SNPs. Single marker differences, as well as the three genotypes
in cases and controls, were accessed using χ2 tests. Data of odds ratio
(OR) and 95% confidence intervals (CIs) were calculated. Haploview
software version 4.1 was used to analyze the association between
haplotypes and the NSCLC, and Bonferroni correction was per-
formed. Haploview software version 4.1 was used to analyze the
association between haplotypes and the disease.
Results
Two hundred patients (65 females and 135 males) and 200 healthy
controls (76 females and 124 males) were of Chinese Han origin. The
mean age in cases and controls was 57.64 years (range, 36–77 years) and
56.66 years (range, 33–80 years), respectively. There were no statis-
tically significant differences among cases and controls in terms of age
and sex distributions. Four hundred subjects (145 ADC, 55 SQC, and
Table 1. Oligonucleotide Sequence Used for Genotyping.
Genes SNPs Primers Sequences
CHRNA3 rs578776 First 5′-ACGTTGGATGCAATGAATAACTAGGCATGA-3′
Second 5′-ACGTTGGATGCCATTTCAGAGAGCTTCAAC-3′
Extension 5′-CTCTTGCATACTTCTAAATTATAC-3′
CHRNA3 rs938682 First 5′-ACGTTGGATGTGCCACTGCCTTTTGTTGTC-3′
Second 5′-ACGTTGGATGAGTGACGGTCACAGCTATTC-3′
Extension 5′-CTCCTGTCACAGCTATTCATCTCTGCCC-3′
CHRNB4 rs7178270 First 5′-ACGTTGGATGTCCCAGGATCACATCTCAAG-3′
Second 5′-ACGTTGGATGGTTTGTTTTAGGTGTCCCAG-3′
Extension 5′-GTGTCCCAGAAGCAAAC-3′
CHRNA5 rs17486278 First 5′-ACGTTGGATGCCATACTAAAACTAAGGAGC-3′
Second 5′-ACGTTGGATGCACAGTCAAATCATTTGGTG-3′
Extension 5′-CTTCCAATCATTTGGTGAAACCACATT-3′
CHRNA5 rs11637635 First 5′-ACGTTGGATGTCTGCTATCCACCCTAGTCG-3′
Second 5′-ACGTTGGATGTTTGCCTAACAGGCATATTC-3′
Extension 5′-TGTGCCTAACAGGCATATTCAGATAC-3′
Table 2. HWE Pearson’s P in Cases and Controls.
Genes rs HWE Pearson’s
P (Control Group)
HWE Pearson’s
P (Case Group)
CHRNA3 rs578776 .63384 .48387
CHRNA3 rs938682 .17306 .77744
CHRNB4 rs7178270 .01339 .93522
CHRNA5 rs17486278 .08356 .87146
CHRNA5 rs11637635 .34578 .24062
Figure 1. Haplotype structure of all markers.
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200 healthy controls) were genotyped for polymorphisms in all genes.
Data for CHRNA3 rs578776 status were available in 199 NSCLC
patients (99.5%) [145 ADC (100%) and 54 SQC (98.2%)] and
199 controls (99.5%). We examined HWE in the controls and cases
separately, and no evidence of deviation from HWE in each gene was
found (Table 2).
Haploview identified one block (Figure 1) in which the fre-
quency of the haplotypes rs17486278/rs11637635/rs578776/
rs938682/rs7178270 of CHRNA5-CHRNA3-CHRNB4 locus was
nonsignificantly different whether between controls and cases or
between controls and subgroups (ADC or SQC; Table 3).
To explore the distributions’ difference of the allele frequencies
and genotype in cases and controls, we performed a statistical analysis
(each OR was adjusted for gender and age). The results are shown
in Tables 4 and 5. In Table 4, all allele frequencies in CHRNA3
(rs578776 and rs938682), CHRNB4 (rs7178270), and CHRNA5
(rs17486278 and rs11637635) are similar between cases and con-
trols (P = .5584, .7743, .2793, .6366, and .7874, respectively). We then
stratified by analysis of histologic type. Compared with control, there
was not a significant difference in ADC (P = .9507, .9657, .4067,
.5524, and .7841, respectively) or in SQC (P = .1306, .4429,
.3059, .9962, and .2548, respectively). In Table 5, for CHRNA3
(rs578776) polymorphism, the genotype frequencies were 4.5% (C/C),
59.3% (T/T), and 36.2% (C/T) in the controls; 5.0% (C/C), 56.3% (T/
T), and 38.7% (C/T) in NSCLC patients; 4.1% (C/C), 59.3% (T/T),
and 36.6% (C/T) in ADC patients; and 7.4% (C/C), 48.1% (T/T),
and 44.4% (C/T) in SQC patients. The differences between the con-
trols and the cases, between the controls and the ADC, and between
the controls and the SQC are not statistically significant (χ2 = 0.3769
and P = .8282; χ2 = 0.0316 and P = .9843; χ2 = 2.3798 and P =
.3043, respectively). Likewise, similar results occurred in CHRNA3
(rs938682), CHRNB4 (rs7178270), and CHRNA5 (rs17486278 and
rs11637635; Table 4).
When analyzing the association between genotypes and the risk
of NSCLC, each OR was adjusted for gender and age. We found
that the G/G genotype in CHRNB4 rs7178270 was critically corre-
lated with reduced risk of NSCLC (OR = 0.553; 95% CI = 0.309–
0.989; P = .0437). However, the association is not significant after
Bonferroni correction (P > .01, 0.05 per five tests); further studies in
larger populations are warranted. When stratified by histologic type,
data revealed that the G/G genotype in CHRNB4 rs7178270 was
strongly associated with reduced risk of SQC (OR = 0.344; 95% CI =
0.161–0.732; P = .0043). The genotypes of the CHRNA3 (rs578776
and rs938682) and CHRNA5 (rs17486278 and rs11637635)
were not significantly different whether between controls and cases or
between controls and subgroups (ADC or SQC).
Discussion
The present study investigated the association between NSCLC risk
and the polymorphisms in CHRNA5-CHRNA3-CHRNB4 gene
cluster in a never-smoking Chinese population. Our study showed
that CHRNB4 (rs7178270) is significantly associated with reduced
risk of SQC in never-smoking Chinese people. Neither CHRNA5 nor
CHRNA3 polymorphism was associated with NSCLC, irrespective of
histologic types.
Nicotine acetylcholine receptor genes are expressed in the key re-
gions of the brain and play an important role in controlling smoking
behavior. Located on chromosome 15q25 [13,14], they initiate the
brain responses to nicotine that binds primarily to these receptors
[15,16]. Tobacco smoking is by far the greatest risk factor for devel-
oping lung cancer [17]. Sequence variants in CHRNA SNPs on
chromosome 15 have been associated with increased (self-reported)
cigarette dose and nicotine dependence [13] and increased risk of
lung cancer in smokers [4,18], whereas association in nonsmokers
was not [18]. CHRNA SNPs that conferred lung cancer susceptibil-
ity in a smoking-independent Japanese manner [19] were associated
with risk of familial lung cancer, whereas association of these SNPs
with smoking status was not significant in Americans [20]. The
Table 3. Haplotype Distribution in Never-smoking Chinese with NSCLC and Controls.
Haplotype Frequencies
Controls NSCLC P Value* ADC P Value* SQC P Value*
GTC 0.417 0.412 .8990 0.423 .8686 0.381 .5016
GTT 0.355 0.345 .7708 0.353 .9423 0.327 .5774
ACT 0.185 0.195 .7186 0.179 .8485 0.236 .2296
GCT 0.037 0.047 .4896 0.044 .6569 0.055 .4012
*Compared with controls.
Table 4. Allele Distribution in Never-smoking Chinese with NSCLC and Controls.
Gene Allele Controls [N = 200; n (%)] NSCLC* (N = 200) ADC* (N = 145) SQC* (N = 55)
n (%) P Value OR (95% CI) n (%) P Value OR (95% CI) n (%) P Value OR (95% CI)
CHRNA3 rs578776
T 308 (77.4) 301 (75.6) 225 (77.6) 76 (70.4)
C 90 (22.6) 97 (24.4) .5584 0.907 (0.653–1.259) 65 (22.4) .9507 1.011 (0.704–1.453) 32 (29.6) .1306 0.694 (0.432–1.116)
CHRNA3 rs938682
T 231 (57.8) 235 (58.8) 167 (57.6) 68 (61.8)
C 169 (42.2) 165 (41.2) .7743 1.042 (0.787–1.380) 123 (42.4) .9657 0.993 (0.732–1.349) 42 (38.2) .4429 1.184 (0.768–1.826)
CHRNB4 rs7178270
C 247 (61.8) 232 (58.0) 170 (58.6) 62 (56.4)
G 153 (38.3) 168 (42.0) .2793 0.855 (0.645–1.135) 120 (41.4) .4067 0.878 (0.644–1.195) 48 (43.6) .3059 0.8 (0.522–1.227)
CHRNA5 rs17486278
A 291 (72.8) 285 (71.3) 205 (70.7) 80 (72.7)
C 109 (27.3) 115 (28.7) .6366 0.928 (0.682–1.264) 85 (29.3) .5524 0.903 (0.646–1.263) 30 (27.3) .9962 0.999 (0.622–1.604)
CHRNA5 rs11637635
A 75 (18.8) 78 (19.5) 52 (17.9) 26 (23.6)
G 325 (81.3) 322 (80.5) .7874 1.05 (0.738–1.493) 238 (82.1) .7841 0.947 (0.640–1.400) 84 (76.4) .2548 1.341 (0.808–2.226)
*Compared with controls.
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inconsistencies in the findings of these studies make it difficult to
determine whether or not CHRNA SNPs were directly associated
with lung cancer risk.
In the present study, CHRNB4 rs7178270 polymorphisms con-
tribute to reduced risk of SQC (OR = 0.344; 95% CI = 0.161–
0.732). However, polymorphisms of CHRNA3 (rs578776 and
rs938682) and CHRNA5 (rs17486278 and rs11637635) are not
associated with NSCLC in never-smoking Chinese people in our
study. This result is in disaccord with the Japanese, African-American,
and European studies [7,8,18]. In the Japanese study, CHRNA
SNPs (rs16969968 in CHRNA5 and rs1051730 in CHRNA3) were
shown to contribute to lung cancer risk in a smoking-independent
manner [19]. In the African-American study, CHRNA5 (rs17486278
and rs11637635) and CHRNA3 (rs578776) were associated with
increased lung cancer risk [8]. CHRNA3 rs938682 variations were
strongly associated with lung cancer risk in Europeans [7]. Together
with our earlier study [21], these differences may be primarily attrib-
uted to the distinct genetic background and the different living envi-
ronments of the Chinese population compared to other populations.
It is important to note that two SNPs in CHRNA3 (rs578776 and
rs938682) were not associated with NSCLC in our study; however,
in 2009, Wu et al. found that the rs6495309 SNP located within the
CHRNA3 was associated with significantly increased lung cancer risk
in smokers [22], and, in 2010, Niu et al. found that the rs3743073
polymorphism in CHRNA3 is predictive for lung cancer risk and is
prognostic in advanced stage NSCLC in Chinese Han population
irrespective of smoking status [23]. However, the factors of gender
and smoking status in the case and control groups were imbalanced in
the study of Niu et al., which might have caused a bias. That data
suggested that CHRNA3 polymorphism may play an important role
in tobacco-inducing lung cancer in Chinese people. However, the sam-
ple size was small, which may increase the chance for spurious findings.
In conclusion, we identified that CHRNB4 rs7178270 poly-
morphisms are significantly associated with reduced risk of SQC in
never-smoking Chinese people.
Acknowledgments
We thank Hailong Liu for his excellent technical support.
References
[1] Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer
J Clin 60, 277–300.
[2] Parkin DM, Pisani P, Lopez AD, and Masuyer E (1994). At least one in seven
cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer 59,
494–504.
[3] Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M, and Comparative
Risk Assessment Collaborating Group (Cancers) (2005). Causes of cancer in the
world: comparative risk assessment of nine behavioural and environmental risk
factors. Lancet 366, 1784–1793.
[4] Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP,
Manolescu A, Thorleifsson G, Stefansson H, Ingason A, et al. (2008). A variant
associated with nicotine dependence, lung cancer and peripheral arterial disease.
Nature 452, 638–642.
[5] Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D,
Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, et al. (2008). A
susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor
subunit genes on 15q25. Nature 452, 633–637.
[6] Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q,
Gu X, Vijayakrishnan J, et al. (2008). Genome-wide association scan of tag SNPs
identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40,
616–622.
[7] Broderick P, Wang Y, Vijayakrishnan J, Matakidou A, Spitz MR, Eisen T,
Amos CI, and Houlston RS (2009). Deciphering the impact of common genetic
variation on lung cancer risk: a genome-wide association study. Cancer Res 69,
6633–6641.
[8] Hansen HM, Xiao YY, Rice T, Bracci PM, Wrensch MR, Sison JD, Chang JS,
Smirnov IV, Patoka J, Seldin MF, et al. (2009). Fine mapping of chromosome
Table 5. Genotypes in Lung Cancer Cases and Controls and Their Association with Risk of Lung Cancer.
Genotype Controls (N = 200) NSCLC* (N = 200) ADC* (N = 145) SQC* (N = 55)
n (%) P Value OR 95% CI n (%) P Value OR 95% CI n (%) P Value OR 95% CI
CHRNA3 rs578776
CC 9 (4.5) 10 (5.0) 1 6 (4.1) 1 4 (7.4) 1
TT 118 (593) 112 (56.3) 86 (59.3) 26 (48.1)
CT 72 (36.2) 77 (38.7) .8282 53 (36.6) .9843 24 (44.4) .3043
TT + CT 190 (95.5) 189 (95.0) .8141 1.117 0.444–2.811 139 (95.9) .863 0.911 0.317–2.620 50 (92.6) .3945 1.689 0.499–5.711
CHRNA3 rs938682
CC 31 (15.5) 35 (17.5) 1 27 (18.6) 8 (14.5) 1
TT 62 (31.0) 70 (35.0) 49 (33.8) 21 (38.2)
CT 107 (53.5) 95 (47.5) .4867 69 (47.6) .5307 26 (47.3) .5975
TT + CT 169 (84.5) 165 (82.5) .5900 1.156 0.681–1.962 118 (81.4) .4442 1.247 0.708–2.199 47 (85.5) .8617 0.928 0.400–2.153
CHRNB4 rs7178270
GG 21 (10.5) 35 (17.5) 1 21 (14.5) 1 14 (25.5)
CC 68 (34.0) 67 (33.5) 46 (31.7) 21 (38.2)
CG 111 (55.5) 98 (49.0) .1156 78 (53.8) .5295 20 (36.4) .0057
CC + CG 179 (89.5) 165 (82.5) .0437 0.553 0.309–0.989 124 (85.5) .2641 0.693 0.363–1.323 41 (74.5) .0043 0.344 0.161–0.732
CHRNA5 rs17486278
CC 10 (5.0) 17 (8.5) 1 11 (7.6) 1 6 (10.9) 1
AA 101 (50.5) 102 (51.0) 71 (49.0) 31 (56.4)
AC 89 (44.5) 81 (40.5) .3335 63 (43.4) .6113 18 (32.7) .128
AC + AA 190 (95.0) 183 (91.5) .163 1.765 0.787–3.956 134 (92.4) .3213 1.56 0.644–3.777 49 (89.1) .1095 2.327 0.806–6.713
CHRNA5 rs11637635
GG 130 (65.0) 127 (63.5) 96 (66.2) 31 (56.4)
AG 65 (32.5) 68 (34.0) 46 (31.7) 22 (40.0)
AA 5 (2.5) 5 (2.5) .9499 3 (2.1) .9504 2 (3.6) .4907
AA + AG 70 (35.0) 73 (36.5) .7543 1.067 0.709–1.607 49 (33.8) .8159 0.948 0.604–1.487 24 (43.6) .62397 1.438 0.784–2.638
*Compared with controls.
Translational Oncology Vol. 5, No. 6, 2012 Association between Polymorphisms and NSCLC Li et al. 451
15q25.1 lung cancer susceptibility in African-Americans. Hum Mol Genet 19,
3652–3661.
[9] Lam WK (2005). Lung cancer in Asian women—the environment and genes.
Respirology 10, 408–417.
[10] Fernández-Rubio A, López-Cima MF, González-Arriaga P, García-Castro L,
Pascual T, MarrónMG, and Tardón A (2008). The TP53 Arg72Pro polymorphism
and lung cancer risk in a population of Northern Spain. Lung Cancer 61, 309–316.
[11] Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I,
Zhang T, Liu N, Daneshmand M, et al. (2005). Erlotinib in lung cancer—
molecular and clinical predictors of outcome. N Engl J Med 353, 133–144.
[12] Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L,
Shepherd FA, and National Cancer Institute of Canada Clinical Trials Group
(2006). Smoking history and epidermal growth factor receptor expression as pre-
dictors of survival benefit from erlotinib for patients with non-small-cell lung
cancer in the National Cancer Institute of Canada Clinical Trials Group study
BR.21. Clin Lung Cancer 7, 389–394.
[13] Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA,
Breslau N, Johnson EO, Hatsukami D, Pomerleau O, et al. (2007). Cholinergic
nicotinic receptor genes implicated in a nicotine dependence association study
targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 16, 36–49.
[14] Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, Saccone NL,
Saccone SF, Bertelsen S, Fox L, et al. (2008). Variants in nicotinic receptors and
risk for nicotine dependence. Am J Psychiatry 165, 1163–1171.
[15] Minna JD (2003). Nicotine exposure and bronchial epithelial cell nicotinic
acetylcholine receptor expression in the pathogenesis of lung cancer. J Clin Invest
111, 31–33.
[16] Stevens VL, Bierut LJ, Talbot JT, Wang JC, Sun J, Hinrichs AL, Thun MJ,
Goate A, and Calle EE (2008). Nicotinic receptor gene variants influence
susceptibility to heavy smoking. Cancer Epidemiol Biomarkers Prev 17,
3517–3525.
[17] Frusch N, Bosquee L, and Louis R (2007). Lung cancer. Epidemiology and
etiologic factors. Rev Med Liege 62, 548–553.
[18] Le Marchand L, Derby KS, Murphy SE, Hecht SS, Hatsukami D, Carmella SG,
Tiirikainen M, and Wang H (2008). Smokers with the CHRNA lung cancer-
associated variants are exposed to higher levels of nicotine equivalents and a
carcinogenic tobacco-specific nitrosamine. Cancer Res 68, 9137–9140.
[19] Shiraishi K, Kohno T, Kunitoh H, Watanabe S, Goto K, Nishiwaki Y, Shimada Y,
Hirose H, Saito I, Kuchiba A, et al. (2009). Contribution of nicotine acetylcholine
receptor polymorphisms to lung cancer risk in a smoking-independent manner in
the Japanese. Carcinogenesis 30, 65–70.
[20] Liu P, Vikis HG, Wang D, Lu Y, Wang Y, Schwartz AG, Pinney SM, Yang P,
Andrade M, Petersen GM, et al. (2008). Familial aggregation of common sequence
variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst 100, 1326–1330.
[21] Zhang Y, Gu C, Shi H, Zhang A, Kong X, Bao W, Deng D, Ren L, and Gu D
(2012). Association between C3orf21, TP63 polymorphisms and environment
and NSCLC in never-smoking Chinese population. Gene 497, 93–97.
[22] Wu C, Hu Z, Yu D, Huang L, Jin G, Liang J, Guo H, Tan W, Zhang M, Qian J,
et al. (2009). Genetic variants on chromosome 15q25 associated with lung cancer
risk in Chinese populations. Cancer Res 69, 5065–5072.
[23] Niu X, Chen Z, Shen S, Liu Y, Zhou D, Zhang J, Li Z, Yu Y, Liao M, Lu S,
et al. (2010). Association of the CHRNA3 locus with lung cancer risk and
prognosis in Chinese Han population. J Thorac Oncol 5, 658–666.
452 Association between Polymorphisms and NSCLC Li et al. Translational Oncology Vol. 5, No. 6, 2012
